Last reviewed · How we verify

standard chemo- or endocrine therapy

Prof. Wolfgang Janni · Phase 3 active Small molecule

standard chemo- or endocrine therapy is a Chemotherapy and endocrine therapy (combination or sequential) Small molecule drug developed by Prof. Wolfgang Janni. It is currently in Phase 3 development for Hormone receptor-positive breast cancer (adjuvant or metastatic setting), Various solid tumors (chemotherapy component).

Standard chemotherapy and endocrine therapy work through distinct mechanisms: chemotherapy damages DNA to kill rapidly dividing cancer cells, while endocrine therapy blocks hormone signaling in hormone-sensitive cancers.

Standard chemotherapy and endocrine therapy work through distinct mechanisms: chemotherapy damages DNA to kill rapidly dividing cancer cells, while endocrine therapy blocks hormone signaling in hormone-sensitive cancers. Used for Hormone receptor-positive breast cancer (adjuvant or metastatic setting), Various solid tumors (chemotherapy component).

At a glance

Generic namestandard chemo- or endocrine therapy
SponsorProf. Wolfgang Janni
Drug classChemotherapy and endocrine therapy (combination or sequential)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Chemotherapy agents (such as taxanes, anthracyclines, or alkylating agents) induce DNA damage and cell cycle arrest, leading to apoptosis in cancer cells. Endocrine therapy (such as tamoxifen, aromatase inhibitors, or fulvestrant) blocks estrogen or progesterone signaling pathways critical for growth of hormone receptor-positive cancers. These are broad therapeutic categories rather than single drugs.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about standard chemo- or endocrine therapy

What is standard chemo- or endocrine therapy?

standard chemo- or endocrine therapy is a Chemotherapy and endocrine therapy (combination or sequential) drug developed by Prof. Wolfgang Janni, indicated for Hormone receptor-positive breast cancer (adjuvant or metastatic setting), Various solid tumors (chemotherapy component).

How does standard chemo- or endocrine therapy work?

Standard chemotherapy and endocrine therapy work through distinct mechanisms: chemotherapy damages DNA to kill rapidly dividing cancer cells, while endocrine therapy blocks hormone signaling in hormone-sensitive cancers.

What is standard chemo- or endocrine therapy used for?

standard chemo- or endocrine therapy is indicated for Hormone receptor-positive breast cancer (adjuvant or metastatic setting), Various solid tumors (chemotherapy component).

Who makes standard chemo- or endocrine therapy?

standard chemo- or endocrine therapy is developed by Prof. Wolfgang Janni (see full Prof. Wolfgang Janni pipeline at /company/prof-wolfgang-janni).

What drug class is standard chemo- or endocrine therapy in?

standard chemo- or endocrine therapy belongs to the Chemotherapy and endocrine therapy (combination or sequential) class. See all Chemotherapy and endocrine therapy (combination or sequential) drugs at /class/chemotherapy-and-endocrine-therapy-combination-or-sequential.

What development phase is standard chemo- or endocrine therapy in?

standard chemo- or endocrine therapy is in Phase 3.

What are the side effects of standard chemo- or endocrine therapy?

Common side effects of standard chemo- or endocrine therapy include Nausea and vomiting, Fatigue, Myelosuppression, Hot flashes (endocrine therapy), Vaginal dryness (endocrine therapy), Alopecia (chemotherapy).

Related